Schrodinger Inc (SDGR)
22.85
-1.19
(-4.95%)
USD |
NASDAQ |
Apr 25, 11:24
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.652B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -18.18% |
| Valuation | |
| PE Ratio | 43.94 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.800 |
| Price to Book Value | 3.012 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
| URL | https://www.schrodinger.com |
| Investor Relations URL | https://ir.schrodinger.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 01, 2024 |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
| URL | https://www.schrodinger.com |
| Investor Relations URL | https://ir.schrodinger.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 01, 2024 |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |